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Abstract
Studies on IL-21–producing follicular helper T cell 








Although treatment with glucocorticoid-induced tumor necrosis factor 
receptor-related protein (GITR) agonistic antibody (DTA-1) has shown 
potent antitumor activity in various tumor models, the underlying 
mechanism is not fully understood yet. Here, I demonstrate that interleukin 
(IL)-21–producing follicular helper T (Tfh) cells play a crucial role in DTA-
II
1-induced tumor inhibition. Administration of DTA-1 increased IL-21 
expression in an antigen specific manner and this led to enhanced antitumor 
cytotoxic T lymphocyte (CTL) activity which was mainly produced by Tfh 
cells. Mice treated with a neutralizing antibody to IL-21 receptor exhibited 
decreased antitumor activity by DTA-1. Moreover, tumor growth inhibition 
by DTA-1 was abrogated in Bcl6fl/flCd4cre mice, which are genetically 
deficient in Tfh cells. Mechanistically, IL-4 is required for the optimal 
induction of IL-21–expressing Th cells by GITR co-stimulation and Bcl6 
and c-Maf mediate this pathway. Thus, my findings identify GITR co-
stimulation as an inducer of IL-21–expressing Tfh cells and provide a 
mechanism for its antitumor activity.
Keyword : GITR, IL-21, Follicular helper T cell, antitumor immunity, Cytotoxic 
lymphocyte, Bcl6
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There were traditional medical treatment against cancer; radiation 
therapy, surgery, and chemotherapy. Radiation therapy uses high doses of 
radiation to kill cancer cells and reduce tumors. Radiation therapy causes 
damages in DNA and slows growth of tumor cells. Cancer cells whose DNA 
is damaged beyond repair stop dividing or die. When the damaged cells die, 
they are broken down and removed by body. Surgery is a procedure in 
which a surgeon removes cancer from patient’s body. Surgery works best for 
solid tumors that are contained in one area. Chemotherapy uses drugs to kill 
cancer cells. Chemotherapy works by stopping or slowing the growth of 
cancer cells, which grow and divide quickly. Chemotherapy is used to cure 
cancer, lessen the chance it will return, or ease cancer symptoms. Although 
these treatments have medical benefits, each of them has clinical limitations. 
Radiation not only kills or slows the growth of cancer cells, it can also affect 
nearby healthy cells. Surgery is restricted to solid tumors and can cause 
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pains in operated sites and infection. Chemotherapy not only kills fast-
growing cancer cells, but also kills or slows the growth of healthy cells that 
grow and divide quickly. Damage to healthy cells may cause side effects, 
such as mouth sores, nausea and hair loss. Due to these limitations, 
researchers found other treatments for cancer patients and immunotherapy is 
developed.
Immunotherapy
Immunotherapy is a strategy to regulate cancer cells using immune 
system of cancer patients. The two main strategy of immunotherapy are 
cellular immunotherapy and antibody immunotherapy. Cellular 
immunotherapy is divided into Chimeric Antigen Receptor (CAR) T cell 
therapy, Adoptive T cell therapy (ACT). Antibody immunotherapy is 
divided into checkpoint blockade therapy and agonistic costimulatory 
antibody therapy. The importance of immunotherapy has been 
acknowledged by the Nobel Prize for physiology or medicine 2018 awarded 
for the discovery of cytotoxic T-lymphocyte-associated protein (CTLA-4) to 
James P. Allison and programmed cell death protein 1 / programmed cell 
death protein ligand 1 (PD-1 / PD-L1) to Tasku Honjo (1). Now 
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immunotherapy has become an established pillar of cancer treatment 
improving the prognosis of many patients with a broad variety of 
hematological and solid malignancies (Figure 1). Numerous clinical and 
preclinical studies about immunotherapy have been reported and significant 
advances have been achieved.
Figure 2. 5 pillars of Cancer Treatment
FDA approved immunotherapeutic medical products are usually utilized 
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alongside treatment already in use, including surgery, radiotherapy and 
cytotoxic chemotherapy (2).
Checkpoint inhibitors
Immune checkpoints are regulators of the immune system. These 
signal pathways are crucial for self-tolerance, which prevents the immune 
system from attacking healthy cells indiscriminately. In tumor 
microenvironment, immune checkpoint signals help tumor cells escape from 
immune surveillance by blocking activation of tumor antigen-specific T 
cells with CTLA-4 signaling pathways and inhibiting tumor cell killing of 
tumor antigen-specific T cells with PD-1 signaling pathways (Figure 2 and 
3). Checkpoint inhibitors were developed to block the immune escape 
signals during antitumor immune responses. Checkpoint inhibitors 
significantly controlled tumor growth in preclinical and clinical models 
(1,3-6). Due to its effectiveness, intensive studies have been conducted 
regarding combinational approaches, perioperative uses, new tumor entities, 
response prediction, toxicity management and use in special patient 
populations. However, the antitumor effect of checkpoint inhibitor was not 
able to cover all the cancer patients and researchers found another strategies 
to care cancer patients.
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Figure 2. Antitumor mechanisms of CTLA-4 blocking antibody
Checkpoint proteins, such as B7-1 / BB7-2 on antigen presenting cells (APC) 
and CTLA-4 on T cells, help keep the body’s immune responses in check. 
When the T-cell receptor (TCR) binds to antigen and major 
histocompatibility complex (MHC) proteins on the APC and CD28 binds to 
B7-1 / B7-2 on the APC, the T cell can be activated. However, the binding 
of B7-1 / B7-2 to CTLA-4 keeps the T cells in the inactive state so they are 
not able to kill tumor cells in the body. Blocking the binding of B7-1/B7-2 
to CTLA-4 with an immune checkpoint inhibitor allows the T cells to be 
6
active and to kill tumor cells.
Figure 3. Antitumor mechanisms of PD-1 / PD-L1 signal blocking 
antibody
Checkpoint proteins, such as PD-L1 on tumor cells and PD1 on T cells, help 
keep immune responses in check. The binding of PD-L1 to PD-1 keeps T 
cells from killing tumor cells in the body. Blocking the binding of PD-L1 to 
PD-1 with an immune checkpoint inhibitor allows the T cells to kill tumor 
cells
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Costimulatory molecule agonistic antibodies
Immune cell function is tightly regulated by costimulatory receptors, 
which are activated in response to exposure to foreign antigens, and co-
inhibitory receptors, which dampen signaling to avoid excessive immune 
activation, tissue damage and autoimmunity (7). Same goes with antitumor 
immune responses. Along with immune checkpoints, costimulatory 
pathways are equally important in driving productive anticancer immunity. 
There are many different costimulatory molecules in immune cells, 
including B7 family, the tumor necrosis factor receptor superfamily. CD28 
and inducible T cell co-stimulator (ICOS) are costimulatory molecules in B7 
family. CD28 is the prototypic costimulatory receptor and a critical mediator 
of T cell signaling following TCR activation (8). Similarly, inducible T cell 
costimulatory (ICOS) is another costimulatory receptor important for the 
function and survival of activated and memory T cells (9,10). The tumor 
necrosis factor receptor superfamily (TNFRSF) is a large and functionally 
diverse class of receptors with related structures capable of mediating a 
range of immune and non-immune cell functions. Of the 29 receptors that 
are known to belong to this family, 6 receptors have been characterized and 
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validated to date to have a primary role as immune co-stimulators 
(TNFRSF5 (also known as CD40), TNFRSF4 (also known as OX40), 
TNFRSF9 (also known as 4-1BB), TNFRSF7 (also known as CD27), 
TNFRSF18 (also known as glucocorticoid-induced TNFR-related protein, 
GITR) and TNFRSF8 (also known as CD30)). These costimulatory 
molecules are expressed on a number of immune cells including T cells, B 
cells, NK cells and antigen presenting cells. Because these costimulatory 
molecules have crucial roles in activation and survival of immune cells, 
therapeutic agonist agents targeting these costimulatory molecules have 
been developed (Table 1).









IgG1 Celldex Phase I/II 





Seattle Genetics Phase I 
RO7009789 IgG2 Roche Phase I/II 
JNJ-64457107 IgG1 Janssen Phase I 
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(ADC1013) 
APX-005M IgG1 Apexigen Phase I 











Leap Therapeutics Phase I 
MK-4166 IgG1 Merck & Co. Phase I 
MK-1248 IgG4 Merck & Co. Phase I 
GWN-323 IgG1 Novartis Phase I 
INCAGN01876 IgG1 Incyte Phase I/II 
BMS-986156 IgG1 Bristol-Myers Squibb Phase I/II 




IgG1 AstraZeneca Phase I 
PF-04518600 IgG2 Pfizer Phase II 
BMS-986178 IgG1 Bristol-Myers Squibb Phase II 





n: phase II 
clinical 
GSK-3174998 IgG1 GlaxoSmithKline Phase I 




IgG2 Pfizer Phase II 
Urelumab 
(BMS-663513) 
IgG4 Bristol-Myers Squibb Phase II 
ICOS GSK-3359609 IgG4 GlaxoSmithKline Phase I 




IgG4 TheraMAB Phase I/II 
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GITR as a target of antitumor immune responses
As mentioned above, GITR is a costimulatory molecule of the tumor 
necrosis factor receptor superfamily and is expressed in a broad range of 
immune cells including T cells, NK cells, and B cells (11). It is well-known 
that the administration of GITR agonists inhibits tumor growth in various 
tumor models and CD4 T cells play essential roles in initiating the antitumor 
immunity induced by the GITR agonistic antibody, DTA-1 (12,13). 
Treatment with GITR agonists reduced the number and suppressive effects 
of regulatory T (Treg) cells (14,15). On the other hand, GITR costimulation
increased the number of effector CD8 T cells in the tumor 
microenvironment and upregulated their cellular metabolism (16-18). 
Recently, the first in-human phase 1 trial of GITR agonistic antibodies 
(TRX518) was performed and the safety profile and immune effects in the 
patients were reported (19). 
Role of IL-9 in antitumor immune responses of DTA-1
Previous study in our lab demonstrated that IL-9 plays a fundamental 
role in the antitumor activity of GITR agonistic antibody, DTA-1 (20). In 
this study, several mechanisms of antitumor immune responses of DTA-1 
11
were revealed. First, GITR costimulation promoted the differentiation of 
naïve CD4 T cells into antitumorigenic Th9 cells rather than protumorigenic 
regulatory T (Treg) cells. Therefore, GITR costimulation shifted the balance 
of CD8 to Treg ratio in tumor tissue and contributed antitumor effect of 
DTA-1. Moreover, GITR costimulation induced IL-9 activated tumor 
antigen specific cytotoxic T lymphocytes via stimulation of dendritic cells
(Figure 4) (21). In addition to the discovery with IL-9, previous researcher
also found that DTA-1 treatment induced IL-21 expression in CD4 T cells, 
and questions arose concerning whether IL-21 mediates the antitumor 
immunity that is induced by DTA-1.
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Figure 3. A schematic illustration of Th9 cell-mediated antitumor 
immunity induced by GITR costimulation.
GITR triggering inhibits iTreg cell generation and promotes Th9 cell 
differentiation. IL-9 production triggers epithelial cells to chemoattract 
dendritic cells into the tumor and enhances the cross-presentation and 
costimulatory capacity of the tumor-infiltrating dendritic cells. These tumor-
antigen-crosspresenting dendritic cells then potentiate tumor-specific CD8+
CTL responses, thereby facilitating tumor regression (21).
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Role of IL-21 in antitumor immunity
IL-21 is a member of the common-γ-chain cytokine family which 
includes IL-2, -4, -7, -9, and -15 (22). IL-21 is produced by NKT cells, Th17 
cells, and follicular helper T cells(Tfh cells) (22) and potently stimulates B 
cells, NK cells, and CD8 T cells. IL-21 is a pleiotropic cytokine and well 
known for its antitumor activities. Treatment with recombinant IL-21 has 
been shown to induce NK cell-mediated antitumor activity via NKG2D (23). 
In addition, IL-21 induced the expansion of cytotoxic CD8 T cells without 
the collateral expansion of Treg cells, a role of which is different from IL-2
(24). In breast cancer patients, CCR4–CCR6–CXCR3– CD4+ T cells were 
expanded in the peripheral blood and promoted the cytotoxicity caused by 
autologous CD8 T cells via IL-21 (25). Furthermore, a combination of 
recombinant IL-21 with rituximab showed a synergistic effect on tumor 
regression in cynomolgus monkeys and improved antibody dependent 
cellular cytotoxicity (ADCC) in human NK cells in vitro (26). With PD-1 
blockades, IL-21 exhibited potent antitumor activity against H22 murine 
hepatocellular carcinoma by increasing CTL-induced cytotoxicity (27). 
Previous study in our lab has also shown that IL-21 exerts antitumor activity 
by restoring the function of TIM-3+PD-1+-exhausted NK cells in MHC 
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class-I deficient tumors (28).
Follicular Helper T (Tfh) cells
T cell help to B cells is a fundamental aspect of adaptive immunity 
and the generation of immunological memory. Follicular helper CD4 T (Tfh) 
cells are the specialized providers of B cell help. Tfh cells were recently 
defined CD4 T cell subset. Tfh cells depend on expression of the master 
regulator transcription factor Bcl6. Distinguishing features of Tfh cells are 
the expression of CXCR5, PD-1, SAP (SH2D1A), IL-21, and ICOS, among 
other molecules, and the absence of Blimp-1 (prdm1). Tfh cells are 
important for the formation of germinal centers. Once germinal centers are 
formed, Tfh cells are needed to maintain them and to regulate germinal 
center B cell differentiation into plasma cells and memory B cells (Figure 5)
(29). Even though the master transcription factor for Tfh cells has not been 
defined yet, Bcl6 is considered as a key transcription factor for Tfh cell 
development (30-32). Tfh cells are essential for the generation of most 
isotype switched and affinity matured antibodies, and therefore they have an 
obvious role in protective immunity against pathogens (33). Antibodies are 
necessary for the control of LCMV infection, and defects in Tfh cells result 
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in failure to control LCMV (34). Tfh cell frequencies are associated with the 
amount and quality of antibody responses against SIV (simian 
immunodeficiency virus, a close relative to HIV) in SIV-infected macaques 
(35). Impaired Tfh cell help to B cells is observed in HIV-infected 
individuals, which appears to exacerbate the difficulty in generating 
neutralizing antibodies against HIV (36). Tfh cells are central players in a 
number of autoimmune diseases, and it is hoped that a greater understanding 
of Tfh cells can result in new therapeutic approaches against major 
autoimmune diseases. Increased frequencies of Tfh-like cells in peripheral 
blood are observed in subsets of patients with Sjogren’s syndrome (37), 
juvenile dermatomyositis (38) and systemic lupus erythematosus (39). Tfh 
cells might contribute to autoimmune diseases both by facilitating aberrant 
generation of autoantibodies and by facilitating the formation or 
maintenance of ectopic follicles, which serve as nucleation points for other 
cells that might be directly pathogenic in the autoimmune disease.
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Figure 4. Germinal center structure and follicular helper T cells
Tfh cells help B cells via cytokines and cell to cell contact interactions. In 
addition, Tfh cells likely provide signals to follicular dendritic cells, the 
third cell type of germinal center triumvirate. Tfh cells are required for the 
formation and maintenance of germinal centers and for the generation of B 
cell memory. The control of these processes hinges on Tfh regulation of 
multiple B cell fate decision, including cell death.
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Tfh cells and its role in antitumor immunity
Althought roles of Tfh cells are expected in allergy, autoimmune 
disease and infectious diseases, roles of Tfh cells in tumor immunity is still 
controversial (40-42). Tumor infiltrating Tfh cells were positively correlated 
with clinical outcomes in breast cancer patients with development of ectopic 
lymphoid organ-like structure (40). In human colorectal cancer, similar 
results were observed (43). However, IL-4 produced by Tfh cells is shown 
to compromise antitumor immunity through accumulation of CD11b+
immunosuppressive myeloid cells in the tumor microenvironment, and Tfh 
cells have protumorigenic activity in diffuse large B cell lymphoma 
(DLBCL) via IL-10 (41,42).
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1.2. Purpose of Research
Several mechanisms of antitumor immune responses of GITR 
costimulation were demonstrated. The initiative roles of CD4 T cells in 
GITR agonistic antibodies were elucidated in mice tumor models (12). 
GITR targeting antibodies directly bind to Treg cells which highly express 
GITR on cell surface and downregulates the frequency of Treg cells (13). 
Mature B cell-deficient JHD mice showed impaired antitumor effect of 
GITR agonistic antibodies indicating the critical role of B cells in these 
antitumor immune responses (44). Further studies described the detailed 
mechanisms of GITR costimulation in aspects of differentiation of IL-9 
producing–CD4 T cells that results in balance shifting of protumorigenic to 
antitumorigenic circumstances (20,21). In addition to IL-9, GITR 
costimulation enhanced production of IL-21 which is well-known for its 
antitumor effects (20,21).
In this study, I tried to demonstrate the role of IL-21 in antitumor 
immune responses of GITR costimulation using DTA-1, GITR agonistic 
antibody. First, I examined the tumor growth of DTA-1 treated mice with 
inhibition of IL-21 signal. Next, I tried to find out which cells produced IL-
19
21 after DTA-1 treatment. After I found the IL-21 producer, I asked cellular 
and molecular mechanisms of IL-21 production. Lastly, I tried to 
demonstrate the requirement of IL-21 producing cells in antitumor immune 
responses of DTA-1 using chemical inhibitor and conditional knockout mice.
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Chapter 2. Materials and Methods
Mice
Six- to eight week-old female C57BL/6 and BALB/c mice were 
purchased from the Charles River Laboratories. Bcl-6fl/fl mice, OT-I mice 
and OT-II mice were purchased from the Jackson laboratory. The CD45.1 
and IL-4Ra-/- mice were kindly provided by J.-O. Kim(International Vaccine 
Institute) and Y.-K. Kim, respectively. The CD4-cre mice were kindly 
provided by Y.-S. Chung. All mice were maintained under specific 
pathogen-free conditions in the animal facility of the Pharmaceutical 
Research Institute at Seoul National University. All animal studies strictly 
adhered to the approved Institutional Animal Care and Use Committee 
protocols (SNU-181214-1) at Seoul National University.
Tumor cell lines
The CT26 (purchased in 2002), TC-1 (purchased in 2006) and 
B16F10 (purchased in 2016) cells were purchased from the ATCC and 
MC38 cell lines were kindly provided from Genentech in 2018. These cell 
lines were cultured in DMEM (Gibco) supplemented with 10% FBS and 1% 
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penicillin-streptomycin (DF10). The B16F10-OVA cells (kindly provided in 
2006 by Dr. K. Rock, University of Massachusetts Medical School, Boston, 
MA) were cultured in DF10 supplemented with 200 μg/ml of geneticin 
(Gibco) and 60 μg/ml of hygromycin (Invitrogen). 
Antibodies and reagents
The fluorochrome conjugated antibodies to mouse CD3ε(145-2C11), 
CD4(RM-4-5), CD8α(53-6.7), CXCR5(L138D7), Streptavidin, anti-human 
IgG(HP6017), IFN-γ(XMG1.2), TNF-α(MP6-XT22), CD107a(1D4B), 
CD138(281-2), CD25(PC61), CD44(IM7), CD62L(MEL-14), CD45.1(A20) 
and CD45.2(104) were purchased from BioLegend. The antibodies to mouse 
PD-1(J43), GL-7(GL7), CD95(15A7) were purchased from eBioscience. 
The mIL-21R-hIgG-Fc was purchased from R&D systems. The 79-6 was 
purchased from Calbiochem. The CFSE were purchased from Invitrogen. 
Antibody staining and flow cytometry analysis
Cells were stained with dye-conjugated antibodies in 1% FBS and 
0.02% azide containing PBS buffer. For intracellular staining, cells were 
restimulated with brefeldin A(GolgiPlug; BD Biosciences) and monensin 
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(GolgiStop; BD Biosciences) for 4 hours. Cytofix-Cytoperm kits (BD 
Biosciences) were used for fixation and permeabilization according to the 
manufacturer’s instructions. An antibody against CD107a was added during 
restimulation. For staining transcription factors, cells were fixed and 
permeabilized with a Foxp3 staining kit (eBioscience).
Transplant tumor models
A total of 2 × 105 CT26 cells were subcutaneously (s.c.) injected 
into the left flank of the BALB/c mice, and 2 × 105 TC-1, MC38 and 
B16F10 cells were subcutaneously (s.c.) injected into the left flank of the 
C57BL/6 mice. Five days later, 600 μg of DTA-1 or the rIgG2b control 
(LTF-2; BioXcell) was intraperitoneally (i.p.) administered. For blocking 
IL-21 signaling, 300 μg of anti-mouse IL-21 receptor (4A9; BioXcell) or the 
rIgG2a control (2A3; BioXcell) was administered every 2 or 3 days starting 
8 days after tumor inoculation. For the Bcl6 inhibition, 1 mg of 79-6 
(Calbiochem) was i.p. injected daily between 8 and 14 days after the tumor 
challenge. Bcl6fl/flCd4Cre mice were s.c. injected with 2 × 105 TC-1 cells, 
and 600 μg of DTA-1 was i.p. administered. The tumor sizes were measured 
with calipers every 2 or 3 days when the tumor cells were palpable.
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In vitro CTL using Calcein-AM
Eight days after DTA-1 injection, the spleen and tumor-draining 
lymph nodes from CT26 tumor bearing mice were harvested and cultured 
with the CT26 epitope AH-1 for 5 days. The CT26 cells were labelled with 
1 μM Calcein-AM (C3100MP; Life Technologies) and cocultured with AH-
1 stimulated effector cells for 4 hours. Using a SpectraMAX M5 (Molecular 
Devices), the fluorescence of the supernatant from the wells with cocultured 
cells was analyzed.
Immunohistology staining of tumor draining 
lymph nodes
Lymph nodes were obtained from CT26 tumor bearing mice 7 days 
after DTA-1 treatment. Obtained lymph nodes were cryoreserved in OCT 
compound. Cryoreserved lymph nodes were 9 μm sectioned using Cryostat 
Microm HM 525 (Thermo Scientific). Sectioned lymph nodes were located
on slide glasses and fixed with acetone for 30 min at -20°C. After fixation, 
Samples were placed in PBS for 30 min at room temperature. Remaining 
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PBS were carefully removed and samples were blocked with blocking 
buffer (0.3% BSA and 0.1% tween in PBS). Fixed samples were stained 
with 100X anti-B220 PE, 400X anti-PNA FITC and anti-CD4 APC 
antibodies at 4°C overnight in the humidifying chamber. On the next day, 
stained samples were washed with wash buffer (0.1% BSA and 0.1% tween 
in PBS) for 3 times. After washing, 1 – 2 drops of Gold solution (Sigma)
were used for developing. Immunohistology images were obtained with 
Confocal scope TC58 (LEICA).
Differentiation of IL-21–producing CD4 T cells in 
vitro
CD4+CD25–CD44loCD62Lhi naïve T cells or CD4+CD25– T cells 
were purified by flow cytometry and stimulated for 4 days with plate-bound 
anti-mouse CD3ε (2 μg/ml, 145-2C11; BioLegend) and anti-mouse CD28 (1 
μg/ml, 37.51; BioLegend) or T cell-depleted splenocytes (1 : 5), 
supplemented with IL-2. To induce IL-21, IL-4 (10 ng/ml; R&D Systems), 
IL-6 (10 ng/ml; Peprotech), IL-12 (10 ng/ml; Peprotech), and IL-27 (10 
ng/ml; Peprotech) were added to culture well of naïve CD4 T cells. For 
some experiments, 2 μg of anti-mIL-4 (11B11; ATCC), anti-mIL-6 
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(MP520F3; R&D Systems), anti-mIL-12/IL-23p40 (C17.8; R&D Systems), 
and anti-mIL-27 p28/IL-30 (AF1834; R&D Systems) were added during 
culture. The accumulated supernatants were collected from the 4-day culture, 
and the IL-21 concentration was determined using an IL-21 ELISA kit 
(Invitrogen) according to the manufacturer’s instructions.
Preparation of tumor infiltrating lymphocytes
Tumor tissues from tumor bearing mice were cut into small pieces 
and dissociated with gentleMACS Dissociator (Miltenyi Biotec). The 
dissociated tumor tissues were digested in 2% FBS RPMI medium 
containing 1 mg/ml collagenase D (Roche), 100 μg/ml hyaluronidase 
(Sigma Aldrich), and 100 μg/ml DNase I (Sigma Aldrich) at 37  for 30 ℃
min. From the digested tumor tissues, the lymphocytes were isolated by 
lymphocyte separation medium (MP Biomedicals) and used for experiments.
c-Maf silencing in CD4 T cells
The scrambled vector used as a control and the c-Maf shRNA 
vector were kindly provided by S.-H. Im.(Division of Integrative 
Biosciences and Biotechnology, Department of Life Sciences, Pohang 
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University of Science and Technology (POSTECH). Retroviral supernatants 
were generated by Platinum-E (Plat-E) retroviral packaging cell lines with 
FuGene HD transfection reagent (Promega) according to the manufacturer’s 
instructions. FACS sorted naïve CD4 T cells were stimulated with plate-
bound αCD3 (2 μg/ml) and αCD28 (1 μg/ml) with 10 ng/ml of IL-2 for 24 
hours and the cells were transduced with retroviral supernatants containing 4 
μg/ml of polybrene by means of spin infection (800 g for 90 min at 37°C). 
After infection, the CD4 T cells were cultured in the presence of plate-
bound αCD3 (2 μg/ml) and αCD28 (1 μg/ml) with IL-4 (10 ng/ml) and 
DTA-1 (2 μg/ml). Eighteen or forty eight hours later, the GFP+ cells were 
sorted and resuspended with TRIzol reagent (Invitrogen) for qPCR analysis.
Preparation of human PBMC
Human peripheral blood cells were obtained from healthy 
volunteers and informed consent was received from all donors. 
Mononuclear cells were isolated by Ficoll-Histopaque (Sigma Aldrich) 
density gradient centrifugation. The collection of human samples and all 
human experiments were approved by the ethical committee of Seoul 
National University (IRB No. 1712/001-003).
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Adoptive transfer model
1:1 mixture of CD4 T cells (2 × 106 each) from the 
CD45.1+CD45.2+ OT-II mice and CD45.1+ B6/SJL mice was intravenously 
injected into the  B16F10-OVA tumor-bearing C57BL/6 mice 9 days after 
tumor challenge. The next day, 600 μg of DTA-1 or rIgG2b control antibody 
was administered, and the tumor-draining lymph nodes were analyzed 7 
days after antibody treatment.
Quantitative PCR
Total RNA was extracted with TRIzol reagent (Invitrogen) and 
reverse transcribed using AmfiRivert cDNA Synthesis Platinum Master Mix 
(GenDEPOT). The synthesized cDNA was quantified with a TB GreenTM
Premix Ex TaqTM (TaKaRa) and the AriaMx 96 Real-Time PCR System 
(Agilent). The expression levels of the target genes were normalized to the 
amount of mHprt expression.
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Immunoblot analysis 
The cytoplasmic fractions of the cells were prepared as follows: in 
vitro cultured CD4 T cells were washed once with ice-cold PBS and 
collected by centrifugation at 5,000 r.p.m. for 10 min. The cells were 
resuspended in RIPA buffer (R0278, Sigma-Aldrich) with 1 mM DTT and 
0.25 mM PMSF, and a proteinase inhibitor cocktail. The mixtures were 
vortexed at high speed for 30 min. The extracts were collected by 
centrifugation at 13,000 r.p.m. for 10 min. The supernatants were collected 
as cytoplasmic extracts. These cell extracts were loaded onto SDS-PAGE 
gels and then transferred to PVDF membranes using iBlot 2 PVDF Mini 
Stacks (Invitrogen). The membranes were stained with specific antibodies 
and chemiluminescence was visualized using an LAS-3000 LuminoImage 
analyzer (Fuji film).
Statistical analysis
Unpaired two-tailed Student’s t tests and two-way ANOVA were 
used for statistical analyses. The results with a P value of < 0.05 were 




IL-21 signaling is essential for DTA-1-induced 
antitumor immunity by potentiating CD8 T cell 
responses.
To examine the role of IL-21 in DTA-1-induced antitumor immune 
responses, I used a well-established tumor models; CT26, TC-1 and MC38. 
BALB/c mice were subcutaneously injected with CT26 cells and were given 
DTA-1 or rIgG2b as a control 5 days after tumor inoculation. Consistent 
with earlier studies (12,13,20,44), the DTA-1 treatment remarkably 
suppressed tumor growth of the CT26 cells; however, administration of the 
anti-IL-21 receptor (αIL-21R) significantly abrogated this tumor inhibitory 
effect in CT26, TC-1 and MC38 model (Figure 5). 
31
Figure 6. Blocking IL-21 signaling compromises antitumor activity of 
DTA-1.
(A, B and C) Balb/c or C57BL/6 mice were subcutaneously injected CT26 
(A), TC-1 (B) or MC38 (C) tumor cells. 5 days after tumor inoculation, 
mouse were intraperitoneally injected with DTA-1 or control rIgG2b 
antibodies. 2 days later, mice were intraperitoneally injected with αIL-21R 
and control rIgG2a antibodies every 2 to 3 days (n=8-9 per each group). 
Tumor size were monitored since 2 days after antibody administration. (A, 
B and C) The data represent at least two experiments. Results were shown 
as mean ± SEM. * P<0.05, ** P<0.01, *** P< 0.005 as determined using 
two way ANOVA.
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Next, I investigated the cellular mechanism by which DTA-1 administration 
triggers antitumor immunity via IL-21. Given that NK cells and CD8 T cells 
play a key role in eliminating tumors and are also known as targets of IL-21
(45-50), I analyzed the production of effector molecules by CD8 T cells and 
NK cells in CT26 tumor bearing mice. Eight days after the DTA-1 treatment, 
production of IFN-ɣ and granzyme B by NK cells were unchanged (Figure 
7). 
Figure 7. DTA-1 does not affect effector molecule secretion from NK 
cells.
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Balb/c mice were subcutaneously injected CT26 tumor cells. 5 days after 
tumor inoculation, mice were intraperitoneally injected with DTA-1 or 
control rIgG2b antibodies. 8 days later, IFN-ɣ (A) and Granzyme B (B)
production in NK cells from TdLN were analyzed using flow cytometry. (A 
and B) The data represent at least two experiments. Results were shown as 
mean ± SEM. * P<0.05, ** P<0.01, *** P< 0.005 as determined using a 
Student’s t-test.
On the other hand, the expression of effector molecules and degranulation 
marker was upregulated by DTA-1 in the CD8 T cells, but was subsequently 
downregulated by αIL-21R treatment (Figure 8). 
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Figure 8. DTA-1 induced IL-21 potentiates CTL responses.
CT26 tumor bearing mice were treated with DTA-1 or αIL-21R antibodies. 
8 days after DTA-1 treatment, spleen and tumor draining lymph node 
(TdLN) cells were harvested and stimulated with CT26 epitope AH-1 for 5 
days. Stimulated effector cells (E) were co-cultured with Calcein-AM 
labelled CT26 cells (T) for 4 hours with indicated ratio. The percentage of 
specific lysis were calculated with the fluorescence from harvested sup. The 
data represent at least two experiments. Results were shown as mean ± SEM. 
* P<0.05, ** P<0.01, *** P< 0.005 as determined using two way ANOVA.
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Consistently, I observed a potent target cell killing activity of CD8 T cells 
from the DTA-1-treated mice which was significantly decreased by αIL-21R 
treatment (Figure 96). In comparison with other immune checkpoint 
blockers, I asked whether DTA-1 take parts in exhaustion state of tumor 
associated CD8 T cells. To see the exhaustion status, I examined the 
inhibitory receptors such as TIM-3, PD-1, 2B4 and LAG3 from CD8 T cells 
in tumor site from DTA-1 treated mice. Surprisingly, DTA-1 induced 
inhibitory receptor expression from tumor infiltrated CD8 T cells 
(Figure10). On the other hand, effector molecule production is also 
increased by DTA-1 (Figure11). From these results, I suggest that DTA-1 
induced inhibitory receptors are early activation marker of tumor infiltrating 
CD8 T cells and DTA-1 is not much associated with exhaustion.
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Figure 9.7 DTA-1 induced IL-21 mediates effector molecule production 
by CD8 T cells.
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CT26 tumor bearing mice were treated with DTA-1 or αIL-21R antibodies. 
8 days after DTA-1 treatment, spleen and tumor draining lymph node 
(TdLN) cells were harvested and stimulated with CT26 epitope AH-1 for 5 
days. After 5 days stimulation, cells were re-stimulated with AH-1 for 4 
hours followed by intracellular staining of IFN-ɣ, TNF-ɑ and CD107a and 
analyzed in CD8 T cells. Representative dot plots (A) and graph data (B) of 
effector molecule production from CD8 T cells are depicted. (A and B) The 
data represent at least two experiments. (B) Results were shown as mean ± 
SEM. * P<0.05, ** P<0.01, *** P< 0.005 as determined using two way 
ANOVA.
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Figure 10. Inhibitory receptor expressions from TIL CD8 T cells.
7 and 10 days after DTA-1 treatment, immune cells harvested from tumor 
tissue of each group are followed by staining of inhibitory receptors 
including TIM-3, PD-1, 2B4 and LAG-3 are analyzed in CD8 T cells. 
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Representative dot plots (A) and graph data (B) of each receptor expressions 
are depicted. (A and B) The data represent at least two experiments. (B)
Results were shown as mean ± SEM. * P<0.05, ** P<0.01, *** P< 0.005 as 
determined using two way ANOVA.
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Figure 11. Effector molecule productions from TIL CD8 T cells.
7 and 10 days after DTA-1 treatment, immune cells harvested from tumor 
tissue of each group are stimulated with PMA, ionomycin for 4 hours and 
followed by staining of IFN-ɣ, TNF-ɑ and CD107a and analyzed in CD8 T 
cells. Representative dot plots (A) and graph data (B) of each molecule 
expressions are depicted. (A and B) The data represent at least two 
experiments. (B) Results were shown as mean ± SEM. * P<0.05, ** P<0.01, 
*** P< 0.005 as determined using two way ANOVA.
In addition to its impact on effector cells, IL-21 is also known as a negative 
regulator of suppressive Treg cells, by affecting differentiation and survival 
(51,52). I also previously reported that DTA-1 hampers the differentiation of 
naïve CD4 T cells into Treg cells which resulted in reduced Treg 
populations in tumor tissue (20). To examine whether DTA-1 induced Treg 
cell decrement is IL-21-dependent, I analyzed the Foxp3+ tumor infiltrating 
lymphocyte (TIL) Treg cell population in tumor bearing mice treated with 
DTA-1 and αIL-21R and found that blocking IL-21 signaling had no effect 
on the TIL Treg population (Figure 12).
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Figure 12. Population of Treg cells are not affected by IL-21 inhibition.
8 days after DTA-1 treatment, population of FoxP3+ Treg cells are analyzed 
in tumor tissues from each group. Representative dot plots (A) and graph 
data (B) of Treg cells are shown. (A and B) The data represent at least two 
experiments. (B) Results were shown as mean ± SEM. * P<0.05, ** P<0.01, 
*** P< 0.005 as determined using two way ANOVA.
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Collectively, these results demonstrate that DTA-1-induced IL-21 facilitates 
the antitumor immune responses by activating CD8 T cells.
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Tfh cells mainly produce IL-21 upon DTA-1 
treatment in tumor-bearing mice.
As previously described (20), treatment of DTA-1 increased IL-21 
expression in the CD4 T cells of tumor-draining lymph node (TdLN) at the 
transcript level (Figure 13A). Next, I examined the kinetics of IL-21 
expression in CD4 T cells followed by DTA-1 treatment and found that the 
IL-21 expression in CD4 T cells was significantly increased at day 4 and 
peaked at day 7 and then dramatically decreased thereafter (Figure 13B). 
Figure 13. DTA-1 increases IL-21 production from CD4 T cells.
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(A and B) Balb/c mice were subcutaneously injected CT26 tumor cells. 5 
days after tumor inoculation, mice were intraperitoneally injected with 
DTA-1 or control rIgG2b antibodies. (A) 6 days after DTA-1 treatment, Il21
mRNA transcript expression of CD4 T, CD8 T and non T cells from TdLN 
of tumor bearing mouse were qPCR analyzed. (B) Kinetic analysis of the 
percentage of IL-21 secreting CD4 T cells from TdLN were shown. (A and 
B) The data represent at least two experiments. (A) Results were shown as 
mean ± SEM. * P<0.05, ** P<0.01, *** P< 0.005 as determined using a 
Student’s t-test. (B) Results were shown as mean ± SEM. * P<0.05, ** 
P<0.01, *** P< 0.005 as determined using two way ANOVA.
To determine the structural changes induced by DTA-1 in TdLN at day 7, I
performed IHC staining. The immunohistological analysis showed that 
treatment with DTA-1 enhanced germinal center responses in vivo (Figure 
14).
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Figure 14. Immunohistology of tumor draining lymph nodes in DTA-1 
treated mice
CT26 tumor bearing mice were treated with DTA-1 or rIgG2b control. 7 
days after DTA-1 treatment, tumor draining lymph nodes sections were 
stained with anti-B220, anti-PNA and anti-CD4 antibodies. The data 
represent two independent experiments.
Given that Tfh cells which mediate germinal center responses are one of the 
well-known cellular sources of IL-21, I investigated whether DTA-1-
induced IL-21 production is found in Tfh cells. As I expected, DTA-1 
treatment increased the frequency of IL-21–producing cells and almost 80% 
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of these cells were coexpressing CXCR5 and PD-1, which are typical 
surface markers for Tfh cells and the number of CXCR5+PD-1+ cells also 
peaked at 7 days after DTA-1 treatment as did the IL-21+ CD4 T cells 
(Figure 15A and B). In addition to frequency, the absolute number of IL-
21–expressing–CXCR5+ PD-1+ cells was also significantly increased in 
DTA-1-treated mice compared to rIgG2b-treated mice (Figure. 15C).
Figure 15. DTA-1 induced IL-21 producing CD4 T cells express CXCR5 
and PD-1.
(A) CXCR5 and PD-1 expression in IL-21 producing CD4 T cells from 
TdLN of DTA-1 treated CT26 tumor bearing mouse. (B) Kinetic analysis of 
CXCR5 and PD-1 expressing cells from TdLN after DTA-1 treatment. (C)
Numbers of IL-21+ CXCR5+ PD-1+ CD4 T cells are described in graph. (A, 
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B and C) The data represent at least two experiments. (B) Results were 
shown as mean ± SEM. * P<0.05, ** P<0.01, *** P< 0.005 as determined 
using two way ANOVA. (C) Results were shown as mean ± SEM. * P<0.05, 
** P<0.01, *** P< 0.005 as determined using Student’s t-test.
Coculture experiments revealed that DTA-1-induced CXCR5+PD-1+ CD4 T 
cells were genuine Tfh cells as they increased IgG production from B cells 
in vitro (Figure 16).
Figure 16. DTA-1 induced CXCR5+PD-1+ CD4 T cells stimulate B cells
in vitro.
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CT26 cells were s.c. injected into BALB/c mice, which were treated with 
DTA-1 7 days after tumor inoculation. After another 7 days later, CXCR5-
PD-1-, CXCR5+PD-1+ CD4 T cells were harvested from TdLNs and 
cocultured with B cells from TdLNs of Ab-free mice in the presence of 
αCD3 and αIgM. Concentration of IgG in the accumulated supernatant
collected from 6-day cocultured wells with indicated conditions. The data 
represent two independent experiments. Results are shown as the mean ± 
SEM. * P<0.05, ** P<0.01, and *** P< 0.005 as determined using Student’s 
t-test.
I also observed that DTA-1 treatment potently induced IL-21–expressing 
CXCR5+PD-1+ Tfh cells in other tumor models such as B16F10, MC38, and 
TC-1 cells (Figure 17). 
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Figure 17. DTA-1 induces IL-21+ Tfh cells in various tumor models
C57BL/6 mice were s.c. injected with each tumor cell line; B16F10, MC38 
or TC-1. Five days after tumor inoculation, the mice were treated with DTA-
1 or control rIgG2b antibodies and TdLNs were analyzed 7 days after DTA-
1 administration. The populations of IL-21+ cells (A), CXCR5+PD-1+ Tfh 
cells (B) and IL-21+CXCR5+PD-1+ Tfh cells (C) in CD4 T cells from 
TdLNs are shown as dot plots and the bar graphs. The data represent two 
independent experiments and results are shown as the mean ± SEM. * 
P<0.05, ** P<0.01, and *** P< 0.005 as determined using Student’s t-test.
I further analyzed tumor-infiltrating lymphocytes and found that IL-21–
producing Tfh cells were also increased by DTA-1 treatment in tumor tissue 
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(Figure 18). 
Figure 18. DTA-1 increases frequency of IL-21+ Tfh cells in tumor tissue
Tumor infiltrating lymphocytes were harvested and followed by staining 
with IL-21, CXCR5 and PD-1 in CD4 T cells. Dot plots of IL-21+ Th cells 
(left) and CXCR5 and PD-1 expression in IL-21+ Th cells (right) (A) and the 
frequency of IL-21+ CD4 T cells (B) in tumor tissue were shown. (A and 
B)The data represent at least two experiments and (B) results were shown as 
mean ± SEM. * P<0.05, ** P<0.01, *** P< 0.005 as determined using a 
Student’s t-test.
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Taken together, I found that DTA-1-induced IL-21 is mainly produced by 
Tfh cells.
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Antigen specific induction of IL-21–producing Tfh 
cells by DTA-1.
Next, I asked whether the induction of IL-21–expressing Tfh cells 
by DTA-1 treatment is antigen-specific. I first compared the frequencies of 
IL-21–expressing Tfh cells in the distal lymph node (distal LN), which is 
the opposite side from tumor injected flank, and tumor draining lymph node 
(TdLN). I found that IL-21–producing CD4 T cells and Tfh cells were only
increased in TdLNs after DTA-1 treatment (Figure 19). 
Figure 19. DTA-1 elevates population of IL-21+ Tfh cells only in 
draining lymph nodes
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7 days after DTA-1 treatment, the percentage of IL-21+ CD4 T cells (A), Tfh 
cells (B) and IL-21+ Tfh cells (C) from ndLN and TdLN are depicted in 
graph. (A, B and C) The data represent at least two experiments and results 
were shown as mean ± SEM. * P<0.05, ** P<0.01, *** P< 0.005 as 
determined using a Student’s t-test.
To directly determine the antigen-specificity, I subcutaneously injected mice 
with B16F10-OVA tumor cells and then adoptively transferred a 1:1 mixture 
of CD45.1+CD45.2+ OVA-specific CD4 T cells and CD45.1+CD45.2-
polyclonal CD4 T cells 9 days after tumor inoculation. Compared to the 
CD45.1+CD45.2- polyclonal CD4 T cells, the IL-21–secreting CXCR5+PD-
1+ Tfh cells were significantly increased in CD45.1+CD45.2+ OVA specific 
CD4 T cells upon DTA-1 treatment (Figure 20). 
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Figure 20. IL-21+ Tfh cells are induced by DTA-1 in antigen specific 
manner
C57BL/6 mouse were subcutaneously injected with 106 B16F10-OVA(MO5) 
cells. 9 days after tumor cell injection, CD4 T cells from CD45.1+ mouse 
and CD45.1+ CD45.2+ OT-II mouse were adoptively transferred into tumor 
bearing mouse. Next day, DTA-1 and control rIgG2b antibodies were i.p. 
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treated. TdLN were harvested and analyzed 7 days after antibodies 
treatment. (A) Contour plots show the IL-21, CXCR5 and PD-1 expression 
from CD45.1+ cells. Red plots show CD45.1+ CD45.2+ OT-II cells and blue 
plots show CD45.1+ cells. The percentage of IL-21+ cells (B), Tfh cells (C)
and IL-21+ Tfh cells (D) are depicted in graph data. (A - D) The data 
represent at least two experiments and (B, C and D) results were shown as 
mean ± SEM. * P<0.05, ** P<0.01, *** P< 0.005 as determined using a 
Student’s t-test.
Taken together, these data suggest that the induction of IL-21+ Tfh cell 
populations by GITR stimulation is an antigen-specific process.
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IL-4 is required for the DTA-1 induced-IL-21–
producing Tfh cells.
Next, I investigated the mechanism by which DTA-1 induces IL-21 
production in CD4 T cells. First, I examined whether DTA-1 stimulation 
directly induces IL-21 production from CD4 T cells in vitro. I found that 
DTA-1 induced IL-21 production from total CD4 T cells (Figure 21). 
Figure 21. DTA-1 stimulation directly induces IL-21 production from
total CD4 T cells
Total CD4 T cells were harvested isolated from pooled spleen and lymph 
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nodes of naïve BALB/c mice and stimulated with αCD3 and αCD28 in the 
presence of DTA-1. Concentration of IL-21 from 4 days accumulated 
supernatant were determined by ELISA. The data represent at least two 
independent experiments. Results are shown as the mean ± SEM. * P<0.05, 
** P<0.01, and *** P< 0.005 as determined using Student’s t-test.
To determine whether IL-21 is produced from effector or naïve CD4 T cells, 
I observed IL-21 production with different initial ratios of naïve and effector 
CD4 T cells. Of interest, neither naïve nor effector derived CD4 T cells 
alone produced IL-21 in response to DTA-1 stimulation, whereas the 
combination of naïve and effector CD4 T cells synergistically produced a 
substantial amount of IL-21 (Figure 22). 
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Figure 22. Both naïve and effector CD4 T cells are required for optimal 
IL-21 production by DTA-1 stimulation
CD4+CD25-CD44-CD62L+ Naïve (N) and CD4+CD25-CD44+CD62L-
effector (E) CD4 T cells were in vitro cultured for 4 days as indicated ratio 
with DTA-1. IL-21 production from each cell ratio are depicted in graphical 
display. The data represent two independent experiments and results were 
shown as mean ± SEM. * P<0.05, ** P<0.01, *** P< 0.005 as determined 
using a Student’s t-test.
To clarify the source of IL-21, I cocultured Thy1.1+CD44+CD62L- cells and 
Thy1.2+CD44-CD62L+ cells stimulated with αCD3 and αCD28 in the 
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presence of DTA-1. I found that IL-21 was produced by only restimulated 
Thy1.2+ CD4 T cells that were derived from CD44-CD62L+ naïve CD4 T 
cells (Figure 23). Taken together, DTA-1 stimulation differentiated naïve 
CD4 T cells into IL-21–producing CD4 T cells.
Figure 23. DTA-1 induced IL-21 is produced by naïve derived CD4 T 
cells
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CD4+CD25-CD44+CD62L- effector CD4 T cells were harvested from Thy 
1.1+ mice and CD4+CD25-CD44-CD62L+ naïve CD4 T cells were harvested 
from Thy 1.2+ mice. 1 : 1 mixture of these cells were stimulated with αCD3 
and αCD28 in the presence of DTA-1. 4 days after stimulation, Thy 1.1+
cells and Thy 1.2+ cells were FACS sorted and stimulated with αCD3 and 
αCD28 respectively. IL-21 concentration from restiumlated supernatant 
were determined by ELISA. The data represent at least two independent 
experiments. Results are shown as the mean ± SEM. * P<0.05, ** P<0.01, 
and *** P< 0.005 as determined using Student’s t-test.
The differentiation of naïve CD4 T cells into each Th subset is 
dependent on cytokine stimulation. Thus, I examined cytokines related to 
IL-21 production in the TdLNs upon DTA-1 treatment. I found that IL-4, -6, 
and -27 but not IL-12 were increased by DTA-1 treatment (Figure 24). 
61
Figure 24. Kinetic analysis of IL-21 associated cytokines
mRNA transcripts of Il4, Il12a, Il12b, Il6 and Il27 are determined after 
DTA-1 treatment. The data represent two experiments and results were 
shown as mean ± SEM. * P<0.05, ** P<0.01, *** P< 0.005 as determined 
using two way ANOVA.
For mechanistic studies, I analyzed IL-21 production from CD4 T cells upon
DTA-1 stimulation in vitro. Neutralizing antibodies to each cytokine showed 
that the IL-21 production increased by DTA-1 stimulation was only reversed 
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by adding antibodies against IL-4 (Figure 25).
Figure 25. IL-4 is required for IL-21 production from GITR 
costimulated CD4 T cells in vitro
IL-21 concentration from accumulated supernatant of in vitro cultured CD4 
T cells stimulated with DTA-1 or control rIgG2b for 4 days with indicated 
cytokine neutralizing antibodies. The data represent two independent 
experiments and results were shown as mean ± SEM. * P<0.05, ** P<0.01, 
*** P< 0.005 as determined using a Student’s t-test.
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Furthermore, while DTA-1 stimulation did not increase IL-21 production 
in naïve CD4 T cells during neutral or other cytokine conditions, it 
dramatically increased IL-21 production in the presence of IL-4 (Figure 26). 
Figure 26. GITR stimulation significantly increases IL-21 production 
from naïve CD4 T cells with IL-4
Concentration of IL-21 from accumulated supernatant of in vitro cultured 
naïve CD4 T cells stimulated with DTA-1 or control rIgG2b with indicated 
cytokines. The data represent two independent experiments and results were 
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shown as mean ± SEM. * P<0.05, ** P<0.01, *** P< 0.005 as determined 
using a Student’s t-test.
Moreover, GITR ligation also promoted IL-21 production in human naïve 
CD4 T cells in the presence of IL-4 (Figure 27), suggesting the important 
role of IL-4 in GITR-induced IL-21 production. 
Figure 27. Human AITR increases IL-21 production from human naïve 
CD4 T cells with IL-4
IL-21 production by human naïve CD4 T cells stimulated with hAITR or 
control mIgG1 under IL-4 condition. The data represent two independent 
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experiments and results were shown as mean ± SEM. * P<0.05, ** P<0.01, 
*** P< 0.005 as determined using a Student’s t-test.
As I demonstrated that both naïve and effector CD4 T cells are required for 
DTA-1 induced IL-21 production in vitro (Figure 22), I hypothesized that 
DTA-1 induced IL-21 is produced by naïve derived CD4 T cells stimulated
with DTA-1 and IL-4 which is produced by effector CD4 T cells. Thus, I 
examined IL-21 production from CD4 T cells comprised of IL-4 receptor-
deficient naïve or effector CD4 T cells. DTA-1 stimulation on CD4 T cells 
produced IL-21 with IL-4 receptor deficiency in effector CD4 T cells. 
However, IL-4 receptor deficiency in naïve CD4 T cells resulted in 
significantly reduced IL-21 production by DTA-1 stimulation in vitro
(Figure 28).
66
Figure 28. IL-4 signal transduction into naïve CD4 T cells is required 
for IL-21 production upon GITR stimulation in vitro.
1 : 1 mixture of CD4+CD25-CD44-CD62L+ naïve and CD4+CD25-
CD44+CD62L- effector CD4 T cells from Il4ra+/+ (WT) or Il4ra-/- (KO) 
mice were cultured for 4 days as the indicated combination with 2μg/ml 
DTA-1 in vitro. The IL-21 production is depicted in the graphical display 
and grey bar represent the wells added with 2μg/ml of αIL-4 neutralizing 
antibodies. The data represent two independent experiments and results are 
shown as the mean ± SEM. * P<0.05, ** P<0.01, and *** P< 0.005 as 
determined using two way ANOVA and Student’s t-test.
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Using IL-4 receptor-deficient mice, I found that the increased frequencies of 
IL-21–producing CD4 T cells as well as Tfh cells upon DTA-1 treatment 
were significantly reduced in IL-4 receptor-deficient mice compared to 
littermate controls in vivo (Figure 29). Altogether, these results suggest that 
IL-4 is essential for IL-21 upregulation by CD4 T cells when GITR 
costimulation is supplemented.
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Figure 29. IL-4 signal is required for IL-21+ Tfh cell induction in vivo.
CT26 tumor bearing Il4ra knockout mice are treated with DTA-1. 7 days 
later, population of IL-21+ CD4 T cells (A and C), Tfh cells (B and D) and 
IL-21+ Tfh cells (E) are depicted. (A - E) The data represent at least two 
experiments. (C – E) Results were shown as mean ± SEM. * P<0.05, ** 
P<0.01, *** P< 0.005 as determined using a Student’s t-test.
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IL-21 induction by DTA-1 is independent from IL-9
Given that DTA-1-induced IL-9 mediates antitumor immune 
responses and that DTA-1-induced IL-9 expression preceded IL-21 
expression, I tested whether the IL-21 induction by DTA-1 is dependent on 
IL-9. I found that neutralization of IL-9 did not alter the frequencies of IL-
21–expressing CD4 T cells or Tfh cells in DTA-1-treated mice (Figure 30A 
and B). In line with this finding, IL-9 did not induce IL-21 production in 
naïve CD4 T cells in vitro (Figure 30C). 
Figure 30. IL-9 is independent from IL-21 production and Tfh
population induction by DTA-1.
(A and B) CT26 tumor bearing mice were treated with DTA-1 5 days after 
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tumor challenge and IL-9 neutralizing antibodies were treated 7, 9 and 11 
days after tumor injection. The percentage of IL-21+ Th cells (A) and Tfh
population (B) in CD4 T cells are shown. (C) Concentration of IL-21 from 
accumulated supernatant of IL-4 or IL-9 and DTA-1 conditioned naïve CD4 
T cells in vitro. (A, B and C) The data represent at least two experiments 
and results were shown as mean ± SEM. * P<0.05, ** P<0.01, *** P< 0.005 
as determined using a Student’s t-test.
Blocking both IL-9 and IL-21 signaling made any significant difference in 
tumor growth from blocking each (Figure 31). Taken together, DTA-1 
induced IL-21 production is independent of IL-9.
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Figure 31. Tumor size from DTA-1, αIL-9 and αIL-21R treated mice.
CT26 tumor bearing mice were treated with DTA-1 5 days after tumor 
challenge followed by IL-9 neutralizing antibody treatment 7, 9 and 11 days 
after tumor injection and αIL-21R antibody treatment 10, 12 and 15 days 
after tumor injection. The data represent two experiments and results were 
shown as mean ± SEM. * P<0.05, ** P<0.01, *** P< 0.005 as determined 
using two way ANOVA.
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c-Maf mediates the development of IL-21–producing
CD4 T cells by IL-4 and DTA-1.
I further dissected the molecular mechanism by which IL-4 and 
DTA-1 stimulation triggers IL-21 expression in CD4 T cells. To this end, I
examined the mRNA expression of the transcription factors related to IL-21 
expression. I found that Maf was markedly increased at the mRNA level by 
stimulation with IL-4 and DTA-1 (Figure 32). 
Figure 32. Expression of IL-21 associated transcription factors from 
naïve CD4 T cells after stimulation with IL-4 and DTA-1
mRNA transcripts from naïve CD4 T cells stimulated with IL-4 and DTA-1 
73
for 18 hours. The data represent at least two experiments. Results are shown 
as the mean ± SEM. * P<0.05, ** P<0.01, and *** P< 0.005 as determined 
using Student’s t-test.
Maf transcript expression peaked at 18 hours of stimulation and c-Maf 
protein was also increased after 2 days of stimulation with IL-4 and DTA-1 
(Figure 33). 
Figure 33. c-Maf is upregulated in IL-4 and DTA-1 stimulated naïve 
CD4 T cells
Expression of c-Maf from the CD4 T cells stimulated with IL-4 and DTA-1 
at the mRNA level (A) and protein level after 2 days of stimulation (B). (A 
and B) The data represent at least two experiments. (A) The data represent 
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at least two experiments. Results are shown as the mean ± SEM. * P<0.05, 
** P<0.01, and *** P< 0.005 as determined using two way ANOVA.
When c-Maf was downregulated using shRNA targeting c-Maf (Figure
34A), the IL-21 expression in CD4 T cells was reduced compared to that of 
control vector-transduced T cells that were stimulated with IL-4 and DTA-1 
(Figure 34B). Collectively, these results suggest that the transcription factor 
c-Maf is important for IL-4 and DTA-1-induced IL-21 production in CD4 T 
cells. 
Figure 34. Downregulation of Maf reduces Il21 production
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(A) The Maf levels from CD4 T cells transduced with Maf–targeting 
shRNA(shMaf) or the control vector under IL-4 and DTA-1 conditions. (B) 
The expression of Il21 mRNA from shMaf transduced CD4 T cells. (A and 
B) The data represent at least two experiments. Results are shown as the 
mean ± SEM. * P<0.05, ** P<0.01, and *** P< 0.005 as determined using 
Student’s t-test.
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Tfh cells play a critical role in the antitumor effect of 
DTA-1.
As I demonstrated the requirement of IL-21 in the antitumor 
immunity induced by DTA-1, I next asked whether Tfh cells are responsible 
for antitumor immunity induced by DTA-1. To address this question, I
harvested Tfh cells and non-Tfh cells from B16F10-OVA tumor-bearing 
mice treated with DTA-1 and cocultured them with OVA-specific OT-I CD8 
T cells for 2 days stimulated with T cell depleted APC and OVA peptide 
(OVA257-264 and OVA329-337). As a result, Tfh cells promoted CFSE dilution 
and IFN-ɣ production in responder OT-I T cells (Figure 35). 
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Figure 35. Tfh cells activate CD8 T cells
Tfh and non-Tfh cells from the TdLNs of B16F10-OVA tumor bearing mice 
treated with DTA-1 were harvested and co-cultured with 5×104 CFSE-
labeled OT-I cells according to the indicated ratios for 2 days. Frequency of 
CFSE-diluted and IFN-ɣ– producing OT-I cells is shown. The data represent 
at least two experiments. Results are shown as the mean ± SEM. * P<0.05, 
** P<0.01, and *** P< 0.005 as determined using Student’s t-test.
To inhibit Tfh cell responses, I adopted small molecule inhibitor 79-6 which 
inhibits transcription factor, Bcl6, that is important for Tfh cell development 
and function(53,54). The Bcl6 inhibition by 79-6 decreased IL-21 
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production in IL-4 and DTA-1 stimulated naïve CD4 T cells (Figure 36)
without inducing any apparent cellular cytotoxicity (Figure 37). 
Figure 36. Bcl6 inhibition reduces IL-21 production
Il21 transcript level (A) and concentration of IL-21 from the accumulated 
supernatant (B) of naïve CD4 T cells cultured with different concentrations 
of 79-6 for 4 days. (A and B) The data represent at least two experiments. 
(A) Results are shown as the mean ± SEM. * P<0.05, ** P<0.01, and *** 
P< 0.005 as determined using two way ANOVA. (B) Results are shown as 
the mean ± SEM. * P<0.05, ** P<0.01, and *** P< 0.005 as determined 
using Student’s t-test.
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Figure 37. Bcl6 inhibition does not induce significant cellular toxicity
IL-4 and DTA-1 stimulated naïve CD4 T cells cultured with 79-6 and 
followed by staining of Annexin V and PI. The data represent two 
experiments.
I next determined the role of Tfh cells in tumor growth inhibition by DTA-1. 
In the CT26 tumor model, administration of 79-6 significantly reduced the 
frequencies of Tfh cells in DTA-1-treated mice and IL-21–producing CD4 T 
cells were also diminished in these mice (Figure 38). 
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Figure 38. Bcl6 inhibition reduces the frequency of DTA-1 induced IL-
21+ Tfh cells in vivo.
BALB/c mice were s.c. injected with CT26 cells, and 5 days later, they were 
i.p. injected with DTA-1 or rIgG2b control antibodies. After 3 days of 
antibody administration, the Bcl6 inhibitor 79-6 or the vehicle control were 
i.p. treated daily for 5 days. (A) CXCR5 and PD-1 expression from the CD4 
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T cells in TdLNs of DTA-1 and 79-6 treated mice is shown in contour plots 
(left) and graph (right). (B) IL-21–secreting CD4 T cells from TdLNs of 
DTA-1 and 79-6 treated mice are shown in contour plots (left) and graph 
(right). (A and B) The data represent at least two experiments. Results are 
shown as the mean ± SEM. * P<0.05, ** P<0.01, and *** P< 0.005 as 
determined using Student’s t-test.
Consequently, tumor growth inhibition by DTA-1 was reversed by 79-6 
treatment (Figure 39). 
Figure 39. Bcl6 inhibition compromises antitumor effect of DTA-1.
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Tumor size from CT26 tumor bearing mice treated as in figure 29 was 
monitored 2 days after DTA-1 injection. The data represent at least two 
experiments. Results are shown as the mean ± SEM. * P<0.05, ** P<0.01, 
and *** P< 0.005 as determined using two way ANOVA.
To confirm the specific requirement of Tfh cells in DTA-1-induced 
antitumor immunity, I used Bcl6fl/flCd4Cre mice in a MC38 and TC-1 tumor 
model. As expected, Bcl6fl/flCd4Cre mice showed reduced frequencies of IL-
21+ Tfh cells in the TdLN (Figure 40). 
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Figure 40. Deletion of Bcl6 in CD4 T cells results in reduced induction 
of IL-21+ Tfh cells by DTA-1.
Bcl6fl/flCd4cre mice were s.c. injected with TC-1, and DTA-1 was treated 
after 7 days. Another 7 days later, TdLNs of tumor bearing mice were 
harvested and analyzed for the expression of IL-21, CXCR5 and PD-1 on 
CD4 T cells. The data represent two independent experiments and results 
are shown as the mean ± SEM. * P<0.05, ** P<0.01, and *** P< 0.005 as 
determined using Student’s t-test.
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Bcl6 deficiency in T cells resulted in impaired DTA-1-induced inhibition of 
tumor growth compared to the control mice in TC-1 and MC38 models 
(Figure 41). 
Figure 41. Antitumor effect of DTA-1 in Bcl6fl/flCd4Cre mice
Tumor size of Bcl6fl/flCd4cre mice which were s.c. injected with MC38 (A) 
and TC-1 (B) and DTA-1 or rIgG2b control antibodies were i.p. treated 5 
days after tumor cell inoculation. (A and B) The data represent two 
independent experiments. Results are shown as the mean ± SEM. * P<0.05, 
** P<0.01, and *** P< 0.005 as determined using two way ANOVA.
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Although Bcl6fl/flCd4Cre mice also have a Bcl6 defect in CD8 T cells, the 
CD8 T cells in these mice produced sufficient IFN-ɣ in response to IL-21 
(Figure 42). Collectively, these results suggest that Tfh cell are required for 
the antitumor activity induced by DTA-1.
Figure 42. Bcl6fl/flCd4Cre CD8 T cells respond to IL-21 in vitro.
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CFSE-labeled CD8 T cells from Bcl6fl/flCd4Cre mice were cultured with 
soluble αCD3 antibody and T cell-depleted antigen presenting cells (APCs) 
at the indicated ratio of IL-21 cytokine are shown. CFSE dilution and IFN-ɣ
production from CD8 T cells are shown in dot plots (A) and graph data (B). 
(A and B) The data represent two independent experiments and results are 
shown as the mean ± SEM. * P<0.05, ** P<0.01, and *** P< 0.005 as 
determined using Student’s t-test.
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Chapter 4. Conclusion
GITR agonism has been a promising strategy for cancer 
immunotherapy and extensive works have demonstrated its cellular 
mechanism in the context of Treg and CD8 T cells (14,16,18,19,55). 
Distinguished from other studies, my research focused on cytokines 
produced by CD4 T cells, and I had previously shown that the GITR 
agonistic antibody exerts antitumor activity in an IL-9–dependent fashion
(20). However, the neutralization of IL-9 did not completely reverse the 
increased CTL activity induced by DTA-1, suggesting that DTA-1 has 
multiple arms of antitumor activity. In this study, I found that IL-21 was 
essential for antitumor CTL responses and subsequent tumor growth 
inhibition by DTA-1 treatment, and production of IL-21 was mainly 
achieved by Tfh cells in an IL-9–independent and antigen specific manner. 
Moreover, I demonstrated that GITR costimulation promoted IL-21 
expression in CD4 T cells with IL-4, via c-Maf. Thus, I have unveiled an 
underlying mechanism of DTA-1–induced antitumor immunity and its 
molecular mechanism for the induction of IL-21–producing CD4 T cells
(Figure 43).
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Figure 43. A schematic illustration of IL-21–producing follicular helper 
T cell-mediated antitumor immunity induced by GITR co-stimulation.
GITR costimulation induced IL-21–producing Tfh cells through IL-4, c-Maf 
signaling pathway. Increased IL-21 signal directly enhanced effector 
molecule production in CD8 T cells and resulted in tumor regression.
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Previous works have demonstrated the mechanism of GITR 
agonism and found that CD4 T cells and mature B cells are responsible for 
antitumor immunity induced by DTA-1 (12,44). Depletion of CD4 T cells 
inhibited the activation of CD8 T, NK and B cells after DTA-1 treatment and 
resulted in uncontrolled tumor growth (12). Another study demonstrated that 
DTA-1 treatment significantly increased B cell responses in tumor bearing 
mice and failed to induce antitumor immunity in mature B cell deficient 
JHD mice with low CTL activity (44). On the basis of the current study, I
suggest that Tfh cells act as a means to account for the role of CD4 T cells 
and B cells in DTA-1 induced antitumor immunity. Although I focused on 
the effects of DTA-1 induced IL-21–producing Tfh cells on CD8 T cells in 
this study, their effects on mature B cells remain for further studies.
Several studies have previously reported the positive role of GITR 
on Tfh cell generation. GITR signaling plays a crucial role in the 
pathogenesis of chronic LCMV infection and collagen-induced arthritis by 
upregulating Tfh cell responses (56,57). However, the role of GITR on Tfh 
cells in tumor microenvironments has not been defined yet. Consistent with 
other models, GITR costimulation increased antigen-specific Tfh cells in 
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tumor–draining lymph nodes and tumor tissues. Although recent clinical 
studies have shown that the frequency of circulating Tfh cells was increased 
in cancer patients, the role of Tfh cells in tumor immunity has been 
controversial (42,58,59). I assume that the role of Tfh cells in tumor 
immunity is determined by the types of tumors. In case of solid tumors, 
tumor infiltrating Tfh cells contribute to the formation of secondary 
lymphoid structure adjacent to tumor site and activate antitumor immune 
responses, including humoral immunity and CTL responses (40). However, 
Tfh cells help tumor growth in diffuse large B cell lymphoma (DLBCL). In 
case of DLBCL, tumor cells are B cells that grow and activate from the help 
of Tfh cells (42). In this context, I suggest that Tfh cells as antitumorigenic 
participants since they potently activated antigen-specific CD8 T cells in 
colon carcinoma models. Furthermore, Bcl6-deficient model confirmed the 
requirement of Tfh cells in DTA-1 induced tumor rejection. 
I observed that CD62L–CD44+ effector CD4 T cells and 
CD62L+CD44– naïve CD4 T cells each produced less IL-21 than the 
coexisting naïve and effector CD4 T cells did upon GITR costimulation
which was mediated by IL-4 signal transduction in naïve CD4 T cells. I
assume from this result that, since most of effector CD4 T cells are 
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differentiated cells, effector CD4 T cells are refractory to re-differentiate 
into IL-21–producing T cells. Also, IL-4 produced by GITR costimulated 
naïve CD4 T cells is not sufficient for IL-21 induction. Both effector and 
naïve CD4 T cells are responsible for optimal IL-21 production by GITR 
costimulation: effector CD4 T cells as IL-4 providers and naïve CD4 T cells 
as IL-21 producers. Recent clinical trial reported that human GITR agonistic 
antibody was not sufficient to mediate substantial clinical responses (19). 
On the basis of my results, the limited efficacy of GITR–targeting 
monotherapy might be due to an insufficient portion of naïve CD4 T cells to 
produce IL-21 in the patients with the late stage cancer.
IL-4 is a typical type 2 cytokine and plays a crucial role in humoral 
immune responses. Previous studies have shown that Tfh cells are also IL-4 
producers, although Th2 cells are considered the main producer of IL-4 (60-
63). Indeed, in a helminth infection model, IL-4 secretion was restricted to 
Tfh cells in an ICOS–dependent manner (64). On the other hand, a recent 
study has also proposed IL-4-committed Tfh cells as precursors of short-
term effector Th2 cells upon house dust mite challenge (60). My findings 
demonstrated that IL-4 was required for the optimal induction of IL-21–
producing Tfh cells upon DTA-1 treatment and human naïve CD4 T cells 
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also produced IL-21 in the presence of IL-4 upon hAITR costimulation. In 
addition, I observed that the frequency of CXCR5+PD-1+ Tfh populations 
was not increased in CT26 tumor bearing IL-4 receptor knockout mice 
treated with DTA-1. To my knowledge, this is the first report to reveal the 
role of IL-4 as an inducer of IL-21–producing Tfh cells. Further studies are 
needed to define a specific requirement of IL-4 and GITR costimulation for 
Tfh cell development and whether agonistic anti-hAITR treatment also 
induces IL-21+ Tfh cells and has antitumor activity through this population 
in human cancer patients.
The roles of c-Maf in Tfh cell development and IL-21 expression 
have been previously described. C-Maf directly binds to the promoter and 
CNS-2 regions of IL-21 gene loci and activates IL-21 expression in CD4 T 
cells (65). Upon IL-21 induction in vitro, c-Maf was transiently upregulated 
among IL-21–regulating transcription factors. ShRNA targeting Maf gene 
indicated that c-Maf mediated IL-21 production in naïve derived CD4 T 
cells with IL-4 and DTA-1. Whether GITR costimulation directly regulates 
c-Maf expression remains to be elucidated.
My study revealed a novel mechanism by which GITR 
costimulation inhibits tumor growth through the induction of IL-21–
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producing Tfh cells. IL-4 plays an important role in IL-21 production in Tfh 
cells upon GITR costimulation via c-Maf. Therefore, my findings provide a 
fundamental basis for the use of GITR agonists to treat cancer and suggest 
IL-21 as a surrogate marker for its effectiveness.
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암의 치료에 대한 면역학적 접근은 세계적으로 많은 연구가 진행
되고 있으며, 항 CTLA-4 항체, 항 PD-1 항체와 같은 면역관문 억
제제는 악성흑색종 치료에 뛰어난 효과를 나타낸다는 사실이 밝혀
졌다. 면역관문 억제제의 항암치료는 기존의 항암치료 방법을 상
회 하는 효과를 보였으나, 모든 암 환자에게 효과가 있는 것은 아
니었다. 이에 면역관문 억제제가 치료하지 못하는 환자들에게 효
과가 있는 새로운 면역항암 치료에 관한 연구가 계속되었고, 대안
으로 공자극 분자 자극 항체에 관한 연구가 진행되었다. 공자극
분자는 면역 세포를 활성화하는 신호를 전달하게 되는데, 공자극
분자 자극을 통해 암을 사멸시킬 수 있는 면역 세포가 활성화될
경우 체내 면역 세포를 이용한 항암효과를 기대할 수 있다. 현재
공자극 분자 중 가장 활발히 연구가 진행되고 있는 GITR 
(glucocorticoid-induced tumor necrosis factor receptor-related protein)은
마우스 모델에서 매우 효과적인 항암효과를 보였으나, 어떠한 기
전으로 항암효과를 나타내는지에 대한 연구는 아직 미흡한 수준이
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었다. 이에 항 GITR 자극 항체의 항암기전을 확인하고자 실험을
계획하였으며 이번 연구를 통하여 항 GITR 자극 항체의 항암기전
으로 Follicular Helper T 세포의 IL-21 생산 유도를 통해 항암면역
작용이 일어난다는 사실을 확인하였다. 먼저 암을 주입한 마우스
에 항 GITR 자극 항체를 복강투여할 경우 암 주변 림프절에서 IL-
21을 발현하는 CD4 T 세포의 증가가 일어나는 것을 확인하였고, 
항 IL-21 수용체 항체를 이용하여 IL-21 신호를 차단하였을 때, 
GITR 자극에 의한 항암효과가 줄어드는 것을 확인하였다. 여러
CD4 T 세포의 아형 중 GITR 자극에 의해 IL-21을 발현하는 아형
은 어떤 것일지 살펴보았고, CXCR5와 PD-1을 발현하는 follicular 
helper T 세포라는 것을 확인하였다. 또한, GITR 자극에 의한 IL-21 
발현에 IL-4가 반드시 필요하며 이 과정에서 c-Maf의 신호전달경
로를 거치게 된다. 
다음으로 GITR 자극에 의해 발현된 IL-21이 어떠한 세포에 영향을
미쳐 항암효과를 나타내는지 확인하였다. GITR 자극 후 IL-21이 생
산된 뒷 시점을 조사하였을 때, 자연살해세포는 활성화되어 있지
않았지만, CD8 T 세포가 활성화되어 있음을 확인하였다. 이에 IL-
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21 신호전달을 차단한 경우 CD8 T 세포가 사이토카인 분비 및 암
세포에 대한 세포독성 효과가 감소하는 현상을 확인하였다. 본 연
구를 통해 GITR 자극이 암 환경에서 Tfh 세포에 의한 IL-21 발현
을 유도하여 항암면역 효과를 나타낸다는 작용기전을 최초로 밝혔
으며, 이에 IL-4의 역할을 규명함으로써 IL-4가 IL-21 유도에 기여
하는 바를 밝혀 GITR 자극 항체의 임상적 적용 시 확인할 수 있
는 새로운 마커를 제시하였다는 것에 의의가 있다.
주요어
GITR 자극 단클론 항체, IL-21, Follicular helper T 세포, IL-4, c-Maf, 





7년 간의 대학원 생활을 마무리 하는 졸업논문을 작성하게 되어
기쁜 마음입니다. 제 졸업논문을 성공적으로 마무리하게 될 수 있
었던 것은 저 혼자만의 힘으로는 부족한 일이었을 것입니다. 가장
먼저 좋은 주제로 연구를 진행할 수 있는 기회를 주신 교수님께
감사드립니다. 또한, 박사학위 졸업논문을 쓰게 되며 논문심사 과
정에서 논문 작성에 많은 도움을 주신 여러 교수님들께 감사의 말
씀 전합니다. 특히나 논문 작성에 많은 도움을 주시고, 논문심사
위원장까지 맡아주신 정연석 교수님께 감사의 말 전합니다. 논문
투고 및 수정 과정에서 많은 아이디어를 주시고, 꼼꼼하게 챙겨주
신 김병석 선배님께 감사의 말 전합니다.
다음으로, 많은 시간을 함께한 우리 실험실 가족들에게 감사의 말
전합니다. 신입생으로 들어와 아무것도 모르는 상태부터 실험하는
방법을 기초부터 알려주고, 후에 주제를 잡고 나서도 어려움이 있
을 때마다 같이 논의를 해주신 김일규선배님께 감사의 말 전합니
다. 실험실에 처음 들어왔을 때, 실험실에서의 생활에 대한 방향성
을 보고 배울 수 있게 해준 박영준 선배님께 감사의 말 전합니다.
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실험실 선배로 많은 본보기를 보여주었던 형석이형에게도 이 자리
를 빌어 감사의 말 전합니다. 실험적으로 많은 토론도 했고, 특히
나 후반부엔 함께 과제를 쓰면서 호흡을 맞춘 보영누나에게 정말
많은 것들 배울 수 있었던 점 감사드립니다. 학부 동기이자 실험
실 선배인 은아에게도 감사의 말 전합니다. 항상 제일 일찍 출근
해서 늦게까지 연구에 매진하는 모습을 옆에서 보며 많은 것을 배
웠습니다. 학부 때부터 동기로 시작해서 실험실에 와서도 함께 생
활하고, 특히 한학기 먼저 졸업한 사람으로 많은 도움을 준 광수
에게 정말 고맙고 미래에 대한 큰 결심한 것 축하하고 높은 자리
까지 올라가길 진심으로 응원합니다. 실험실 동기로 들어온 인수
형에게 항상 고마웠던 마음 여기에서 전합니다. 형이지만 늘 편하
게 대해줘서 함께 하는 실험실 생활이 즐거우면서도 많이 의지가
되었습니다. 최근에 물어볼 일들이 많이 생기곤 하는데, 본인이 바
쁜 와중에도 늘 친절히 알려주는 모습을 보며 많이 배웠습니다.
하나뿐인 박사 후배 정미에게 감사의 말 전합니다. 긴 시간은 아
니지만 함께 실험 했을 때, 대학원에 들어온 지 얼마 안 된 시점
이었는데도 금방 배우고 너무나 잘 해 주어서 정말 많은 도움이
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되었습니다. 가끔씩 약과 관련해서 물어보거나 도움을 청할 때도
많은 도움을 줬던 것도 항상 감사합니다. 실험실 공식 막내 태승
이에게도 이 자리를 빌어 감사의 말 전합니다. 실험실에 와서 실
험만 배우기도 힘들었을 텐데, 야무지게 행정관련 일들 처리 하느
라 정말 고생 많았고, 덕분에 우리 실험실이 잘 유지될 수 있었습
니다. 마지막에 같이 졸업 준비하면서 고생이 많았는데, 이제 잘
마무리 되었으니 취업한 회사에서 새로운 사람들 만나서 즐겁게
잘 지내길 바랍니다.
다음으로 힘든순간에도 버팀목이 되어준 우리 가족들에게 감사의
말을 전합니다. 먼저, 할아버지 할머니께 감사의 말씀 전합니다.
바쁘다는 이유로 자주 연락드리지 못하는 못난 손자도 항상 아껴
주시고 걱정해주셔서 감사드립니다. 할아버지 할머니 두 분 모두
건강히 오래오래 사시면서 손자 손녀들을 비롯한 우리 가족 모두
행복하게 잘 살아가는 모습 지켜봐주시길 부탁드립니다. 다음으로
우리 집안의 가장으로 중심을 잡아준 아버지에게 감사의 말씀 전
합니다. 아버지께서 내려주신 튼튼한 뿌리 덕분에 무사히 박사학
위를 받을 수 있었습니다. 그리고 늘 세심하게 보살펴 주신 어머
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니에게 감사의 말씀 전합니다. 어머니로, 또 먼저 박사학위 받아
본 선배로 해주신 많은 말씀들이 힘든 순간에 큰 도움이 되었습니
다. 새로운 결정을 앞두고 고민이 많을 형에게도 고마움의 말을
전합니다. 대학원을 다니게 되고, 나와서 살게 되면서부터 자주 보
진 못했지만, 제게 필요한 건 없을까 챙겨주던 형의 마음 씀에 항
상 고마웠습니다. 이제 큰 결정을 앞두고 있는데, 신중하게 고려한
선택이니 분명 좋은 결과가 있을거라 생각합니다. 그리고 장인어
른과 장모님께도 늘 가지고 있던 감사한 마음 이 자리를 빌어 전
합니다. 아직 아무것도 결정된 것이 없는 대학원생이었던 저에게
소중한 따님과의 결혼을 허락해주셔서 정말 감사드립니다. 이제
졸업하고 학생의 신분을 벗어나는 만큼, 기대해주신 것에 부응할
수 있도록 성혜와 행복한 삶 꾸며가는 모습 보여드리도록 하겠습
니다. 마지막으로, 사랑하는 부인, 성혜에게 가장 큰 고마움 전합
니다. 대학원신입생과 회사 신입사원으로 처음 만나 결혼하고, 졸
업하는 지금까지 항상 곁에서 힘이 되어 주어 정말 고맙습니다.
처음 만날 때부터 하던 졸업하겠다는 이야기를 6년이 지난 지금에
서야 지키게 되었습니다. 함께 해준 덕분에 힘든 순간도 긍정적으
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로 생각하며 지나갈 수 있는 힘을 키울 수 있었고, 앞으로 고난이
온다 해도 함께라면 잘 헤쳐나갈 수 있을 것 같다는 자신감을 갖
게 되었습니다. 적극적으로 믿어주고 지지해 주었기에 미국에 함
께 가겠다는 큰 결심도 내릴 수 있었습니다. 그동안 우리 집의 가
장으로서 책임 때문에 어깨가 많이 무거웠을 텐데 이제는 함께 나
눠지도록 해요. 정말 고생 많았고, 고맙고 사랑합니다. 제일 마지
막으로 우리 고양이 모모에게도 감사함과 미안함의 말 전합니다.
그동안 바쁘다고 많이 못놀아줘서 미안해. 이제 새로운 낚시대로
더 신나게 놀아줄게. 쫓아다니면서 우다다도 많이해줄게. 아프지
말고 오래오래 함께 살자 모모야. 사랑해.
많은 분들의 도움 덕분에 지금 이 자리에 올 수 있었단 사실을 너
무나 잘 알고 있습니다. 미처 감사의 말에 올리지 못한 많은 분들
께 감사의 말씀을 전합니다. 학부를 졸업하고 실험실 생활을 하며
앞으로 살아가는 자세에 대하여 많은 고민을 하며 혼자만의 힘으
로 이룰 수 있는 것은 없으며, 끊임없이 노력하고 겸손한 자세로
정진해야 한다는 것을 배우게 되었습니다. 제가 배운 바를 항상
잊지 않고 앞으로 나아가는 모습 보여드리도록 하겠습니다.
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